A warning has been issued by Tibotec, the manufacturers of Prezista (darunavir) regarding the risk of developing drug-induced hepatitis while taking the treatment. Apparently, 0.5% of clinical trial participants who took a combination including darunavir (boosted with ritonavir) developed severe hepatotoxicity. Anyone with a history of liver-related complications such as hepatitis B or C are particularly susceptible, so appropriate tests prior to starting darunavir and regular monitoring while on the drug are vital to avoid developing any hepatotoxic reaction. http://www.ashm.org.au